Cyclerion to Present at the J.P. Morgan Healthcare Conference

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/18/2026

1. NVDA
2. DOO
3. ARGX
4. HD
5. SPY

6. METC
7. FN
8. KLAR
9. AMLX
10. VNET

Get Alerts CYCN Hot Sheet

Price: $4.01 -0.5%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

– Management to review the Company's sGC clinical pipeline programs: praliciguat for diabetic nephropathy, olinciguat for sickle cell disease, and IW-6463 for neurodegenerative diseases –

CAMBRIDGE, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it will present at the J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 9AM PST (6AM EST) at the Westin St. Francis in San Francisco in the Elizabethan A Room. The company will also present ongoing and future clinical development plans.

A live webcast of the presentation can be accessed at: https://jpmorgan.metameetings.net/events/hc20/sessions/29869-cyclerion/webcast. An archived replay of the webcast will be available for approximately 90 days following the presentation.

About Cyclerion Therapeutics Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion is advancing its portfolio of differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs include praliciguat which recently completed Phase 2 studies and which the company intends to out-license for further development in diabetic nephropathy, olinciguat in Phase 2 development for sickle cell disease, IW-6463 in Phase 1 development for serious and orphan CNS diseases, and two preclinical programs targeting serious liver and lung diseases, respectively.

For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).

Contact Carlo Tanzi, Ph.D. Kendall Investor Relations 617-914-0008 [email protected]